Evaluation of Procalcitonin and hs-CRP Levels in Sudden Sensorineural Hearing Loss

Sercan Göde, Göksel Turhal, İsa Kaya, Halil İbrahim Mavili, Tayfun Kirazlı
Department of Otolaryngology, Ege University School of Medicine, İzmir, Turkey

OBJECTIVE: The aim of this study was to evaluate procalcitonin and high sensitive c-reactive protein (hs-CRP) levels in idiopathic sudden sensorineural hearing loss (ISSNHL) patients and assess their correlations with the clinical prognosis.

MATERIALS and METHODS: Twenty-three ISSNHL patients were included in the study (group A). The control group was consisted of 19 patients (group B). Procalcitonin and hs-CRP levels were compared between the groups. The relationship between procalcitonin and hs-CRP levels and the configuration of the audiogram, degree of hearing loss (partial or total (>90 dB)), and status of improvement (improvement of >15 dB in the first month PTA) were evaluated.

RESULTS: The mean age was 47.91±15.73 years (range 21–73 years) and 35.16±15.67 years (range 19–79 years) in groups A and B, respectively. Seven patients (30.4%) had underlying cardiovascular risk factors. Mean procalcitonin levels were 0.057±0.025 µg/L and 0.041±0.016 µg/L in groups A and B, respectively. Mean hs-CRP levels were 0.461±1.335 mg/dL and 0.129±0.125 mg/dL in groups A and B, respectively. Procalcitonin levels were significantly higher in group A than in group B (p=0.018). Procalcitonin levels were significantly lower (0.035±0.013 µg/L vs. 0.061±0.025 µg/L) in patients with low-frequency hearing loss (p=0.04). ROC analysis of procalcitonin values revealed that area under the curve was 0.80 (p=0.005). A cut-off procalcitonin level of 0.45 µg/L yielded a sensitivity of 90% and specificity of 56.2%.

CONCLUSION: In conclusion, as a proinflammatory marker, procalcitonin levels were higher in ISSNHL patients than in healthy controls. The procalcitonin level was significantly lower in upsloping-type hearing loss patients. This finding could be regarded as an indirect indicator of pathogenesis.

KEYWORDS: Procalcitonin, hs-CRP, inflammation, sudden sensorineural hearing loss
Patient Selection
Twenty-three ISSNHL patients were included in the study (group A). The control group was consisted of 19 patients (group B). Patients with an acute onset (72 h) of sensorineural hearing loss over 30 dB in at least 3 consecutive frequencies in PTA were included in the study. Retrocchlear pathology, a history of malignancy, and pediatric age were the exclusion criteria. Patients with conditions associated with high procalcitonin levels, such as active infection, thyroid disease, renal failure, chronic liver or intestinal disease, and chronic obstructive pulmonary disease, were also excluded.

Procedure
The procalcitonin and hs-CRP levels were measured after the diagnosis of ISSNHL was established and before any treatments were initiated. All the control patients were recruited from the healthy scheduled septoplasty patients, and their procalcitonin and hs-CRP levels were measured along with other routine blood tests during preoperative anesthesia evaluation.

Pure-tone audiometry was repeated a month later. An increase of >15 dB in the average hearing level (arithmetic mean of 500, 1000, 2000, and 4000 Hz frequencies) was considered as an improvement. The configuration of PTA (upslope, downslope, or flat) was noted. The presence of vestibular symptoms and cardiovascular risk factors (hypertension, coronary artery disease, or diabetes mellitus) was also noted.

Outcome measures
Procalcitonin and hs-CRP levels were compared between the groups. The relationship between procalcitonin and hs-CRP levels and the configuration of the audiogram, degree of hearing loss (partial or total (>90 dB)), status of improvement (improvement of >15 dB in the first month PTA) were evaluated.

Statistical Analysis
Statistical analysis was performed using computer software (Statistical Package for the Social Sciences version 22.0, Inc.; Chicago, IL, USA). Chi-square (X$^2$) exact tests were used for the comparison of categorical data. Independent and paired-sample t-tests were used for the analysis of parametric variables, while Wilcoxon and Mann–Whitney U tests were used for the analysis of nonparametric variables based on the distribution pattern of the data. The Shapiro–Wilk test was used for determining the distribution pattern of the data. The distribution of the groups was nonparametric. Correlation analysis was performed via Pearson or Spearman correlation analysis based on the distribution pattern of the data. Data were expressed as “median, interquartile range (IQR).” Receiver operating characteristic (ROC) analysis was performed. A p-value less than 0.05 was considered statistically significant.

RESULTS
The mean age was 47.91±15.73 years (range 21–73 years) and 35.16±15.67 years (range 19–79 years) in groups A and B, respectively. Of the 42 subjects, 24 were male and 18 were female. Fourteen (60.9%) of the patients were male and 9 (39.1%) were female in group A. Ten (52.6%) of the patients were male and 9 (47.4%) were female in group B. The groups did not differ significantly with regard to the frequency of gender (p>0.05). Seven patients (30.4%) had underlying cardiovascular risk factors (5 had diabetes mellitus; 1 had diabetes mellitus and hypertension; and 1 had diabetes mellitus, hypertension, and coronary artery disease) and 3 (13%) had complaints of vertigo.

Mean procalcitonin levels were 0.057±0.025 µg/L and 0.041±0.016 µg/L in groups A and B, respectively. Mean hs-CRP levels were 0.461±1.335 mg/dL and 0.129±0.125 mg/dL in groups A and B, respectively. Procalcitonin levels were significantly higher in group A than in group B (p=0.018). Hs-CRP levels were also higher in group A; however, this difference was not significant (p=0.287).

There was an improvement in the average PTA findings of 12 (52.2%) patients, while no improvement was recorded in 11 patients (47.8%). The procalcitonin and hs-CRP levels were not statistically different between the patients who did and did not show improvement (p=0.056 and p=0.321, respectively). Procalcitonin levels in patients who did and did not show improvement were 0.048 µg/L and 0.068 µg/L, respectively.

Procalcitonin and hs-CRP levels of the patients who had profound (>90 dB) hearing loss were compared with those of the patients who had less severe hearing loss (<90 dB). Procalcitonin and hs-CRP levels did not differ significantly between patients who had severe hearing loss and those who had less severe hearing loss (p=0.534 and p=0.256, respectively).

The configuration of PTA was downslope in 5 patients (21.7%), upslope in 4 patients (17.4%), and flat in 14 patients (60.9%). Mean procalcitonin levels were 0.035, 0.054 and 0.064 µg/L in upsloping, downsloping, and flat groups, respectively. Neither Kruskal–Wallis nor ANOVA test yielded a statistically significant difference in both procalcitonin and hs-CRP levels. Similarly, pairwise post-hoc analysis
with Bonferroni correction in order to overcome type 1 error yielded nonsignificant results. Flat and downsloping PTA configurations were combined and compared with upsloping ones by Mann–Whitney U test. This analysis revealed a significantly lower procalcitonin level in case of the upsloping PTA configuration (0.035±0.013 µg/L vs. 0.061±0.025 µg/L) (p=0.04).

Receiver operating characteristic analysis was performed to assess the relationship between the procalcitonin level and ISSNHL positive state. ROC analysis of procalcitonin values revealed that area under the curve was 0.80 (p=0.005). A cut-off procalcitonin level of 0.45 µg/L yielded a sensitivity of 90% and specificity of 56.2% (Figure 1).

**DISCUSSION**

It is well known that procalcitonin levels increase significantly in the presence of bacteremia and sepsis. Although procalcitonin is primarily used to help guide physicians to support the presence of bacterial infections, previous research has reported slightly elevated procalcitonin levels during localized bacterial infection and viral infection. In a recent review, hs-CRP was reported to be a valid tool to identify people at a risk of cardiovascular events independent of their demographic background. Xie et al. suggested that hs-CRP is associated with internal carotid artery occlusion in ischemic stroke patients. Because vascular and inflammatory conditions are the most postulated etiologies, procalcitonin and hs-CRP levels in ISSNHL patients were assessed.

Masuda et al. investigated whether inflammatory markers, including leukocyte counts, natural killer cell activity (NKCA), interleukin 6 (IL-6) level, tumor necrosis factor level, and high-sensitivity CRP level, are involved in the pathophysiology of idiopathic sensorineural hearing loss. They suggested that neutrophil counts above the reference range could be a useful indicator of poor prognosis of ISSNHL; however, hs-CRP did not seem to be a useful biomarker. Similarly, hs-CRP levels were not significantly higher in ISSNHL patients than in controls in this study. Hs-CRP levels were also not related to the prognosis, degree of hearing loss, and configuration of PTA. Hs-CRP levels are higher in women and tend to increase with age; however, a similar relationship was observed with procalcitonin levels in large population-based studies. The procalcitonin level was higher in ISSNHL patients than in healthy controls. The procalcitonin level was higher in patients with poor prognosis; however, this difference could not reach a statistically significant level. In addition, control PTA was obtained a month after the diagnosis. It is known that the sensorineural healing process continues for months. Therefore, the prognostic value could be supported with a longer follow-up.

In conclusion, as a proinflammatory marker, procalcitonin levels were higher in ISSNHL patients than in healthy controls. The procalcitonin level was higher in patients with poor prognosis; however, this difference could not reach statistical significance. The procalcitonin level was significantly lower in upsloping-type hearing loss patients. This finding could be regarded as an indirect indicator of pathogenesis.

**Ethics Committee Approval:** All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

**Informed Consent:** Written informed consent was obtained from patients who participated in this study.

**Peer-review:** Externally peer-reviewed.


**Conflict of Interest:** No conflict of interest was declared by the authors.

**Financial Disclosure:** The authors declared that this study has received no financial support.

**REFERENCES**


